Literature DB >> 33210151

β-Adrenoceptor blockade prevents carotid body hyperactivity and elevated vascular sympathetic nerve density induced by chronic intermittent hypoxia.

Abdulaziz A Alzahrani1,2, Lily L Cao1,3, Hayyaf S Aldossary1,4, Demitris Nathanael1, Jiarong Fu1, Clare J Ray1, Keith L Brain1,3, Prem Kumar1, Andrew M Coney5, Andrew P Holmes6,7.   

Abstract

Carotid body (CB) hyperactivity promotes hypertension in response to chronic intermittent hypoxia (CIH). The plasma concentration of adrenaline is reported to be elevated in CIH and our previous work suggests that adrenaline directly activates the CB. However, a role for chronic adrenergic stimulation in mediating CB hyperactivity is currently unknown. This study evaluated whether beta-blocker treatment with propranolol (Prop) prevented the development of CB hyperactivity, vascular sympathetic nerve growth and hypertension caused by CIH. Adult male Wistar rats were assigned into 1 of 4 groups: Control (N), N + Prop, CIH and CIH + Prop. The CIH paradigm consisted of 8 cycles h-1, 8 h day-1, for 3 weeks. Propranolol was administered via drinking water to achieve a dose of 40 mg kg-1 day-1. Immunohistochemistry revealed the presence of both β1 and β2-adrenoceptor subtypes on the CB type I cell. CIH caused a 2-3-fold elevation in basal CB single-fibre chemoafferent activity and this was prevented by chronic propranolol treatment. Chemoafferent responses to hypoxia and mitochondrial inhibitors were attenuated by propranolol, an effect that was greater in CIH animals. Propranolol decreased respiratory frequency in normoxia and hypoxia in N and CIH. Propranolol also abolished the CIH mediated increase in vascular sympathetic nerve density. Arterial blood pressure was reduced in propranolol groups during hypoxia. Propranolol exaggerated the fall in blood pressure in most (6/7) CIH animals during hypoxia, suggestive of reduced sympathetic tone. These findings therefore identify new roles for β-adrenergic stimulation in evoking CB hyperactivity, sympathetic vascular hyperinnervation and altered blood pressure control in response to CIH.

Entities:  

Keywords:  Adrenaline; Beta-blockers; Carotid body; Chronic intermittent hypoxia; Hypertension; Hypoxia; Vascular sympathetic nerves; β-Adrenoceptors

Mesh:

Substances:

Year:  2020        PMID: 33210151      PMCID: PMC7782391          DOI: 10.1007/s00424-020-02492-0

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  77 in total

Review 1.  Peripheral chemoreceptors: function and plasticity of the carotid body.

Authors:  Prem Kumar; Nanduri R Prabhakar
Journal:  Compr Physiol       Date:  2012-01       Impact factor: 9.090

2.  Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.

Authors:  Sonia Maccari; Maria Buoncervello; Andrea Rampin; Massimo Spada; Daniele Macchia; Luciana Giordani; Tonino Stati; Claudia Bearzi; Liviana Catalano; Roberto Rizzi; Lucia Gabriele; Giuseppe Marano
Journal:  Br J Pharmacol       Date:  2016-11-30       Impact factor: 8.739

3.  The carotid chemoreceptor contributes to the elevated arterial stiffness and vasoconstrictor outflow in chronic obstructive pulmonary disease.

Authors:  Devin B Phillips; Craig D Steinback; Sophie É Collins; Desi P Fuhr; Tracey L Bryan; Eric Y L Wong; Vincent Tedjasaputra; Mohit Bhutani; Michael K Stickland
Journal:  J Physiol       Date:  2018-04-11       Impact factor: 5.182

4.  Attenuation of heart rate control and neural degeneration in nucleus ambiguus following chronic intermittent hypoxia in young adult Fischer 344 rats.

Authors:  B Yan; G K Soukhova-O'Hare; L Li; Y Lin; D Gozal; W B Wead; R D Wurster; Z J Cheng
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

5.  EPAC signalling pathways are involved in low PO2 chemoreception in carotid body chemoreceptor cells.

Authors:  Asuncion Rocher; Ana I Caceres; Laura Almaraz; Constancio Gonzalez
Journal:  J Physiol       Date:  2009-07-06       Impact factor: 5.182

6.  β-adrenergic regulation of late Na+ current during cardiac action potential is mediated by both PKA and CaMKII.

Authors:  Bence Hegyi; Tamás Bányász; Leighton T Izu; Luiz Belardinelli; Donald M Bers; Ye Chen-Izu
Journal:  J Mol Cell Cardiol       Date:  2018-09-18       Impact factor: 5.000

7.  Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas.

Authors:  Ying-Jie Peng; Jeffrey L Overholt; David Kline; Ganesh K Kumar; Nanduri R Prabhakar
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-07       Impact factor: 11.205

8.  Carotid Body Ablation Abrogates Hypertension and Autonomic Alterations Induced by Intermittent Hypoxia in Rats.

Authors:  Rodrigo Del Rio; David C Andrade; Claudia Lucero; Paulina Arias; Rodrigo Iturriaga
Journal:  Hypertension       Date:  2016-07-05       Impact factor: 10.190

9.  Oxygen sensitivity of mitochondrial function in rat arterial chemoreceptor cells.

Authors:  Keith J Buckler; Philip J Turner
Journal:  J Physiol       Date:  2013-05-13       Impact factor: 5.182

10.  Dynamic monitoring of single-terminal norepinephrine transporter rate in the rodent cardiovascular system: A novel fluorescence imaging method.

Authors:  Lily L Cao; Andrew P Holmes; Janice M Marshall; Larissa Fabritz; Keith L Brain
Journal:  Auton Neurosci       Date:  2019-12-26       Impact factor: 3.145

View more
  2 in total

Review 1.  The Role of Pharmacological Treatment in the Chemoreflex Modulation.

Authors:  Anna Langner-Hetmańczuk; Stanisław Tubek; Piotr Niewiński; Piotr Ponikowski
Journal:  Front Physiol       Date:  2022-06-14       Impact factor: 4.755

2.  Mitochondrial Succinate Metabolism and Reactive Oxygen Species Are Important but Not Essential for Eliciting Carotid Body and Ventilatory Responses to Hypoxia in the Rat.

Authors:  Agnieszka Swiderska; Andrew M Coney; Abdulaziz A Alzahrani; Hayyaf S Aldossary; Nikolaos Batis; Clare J Ray; Prem Kumar; Andrew P Holmes
Journal:  Antioxidants (Basel)       Date:  2021-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.